73 related articles for article (PubMed ID: 27735138)
1. Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators.
Kraege S; Köhler SC; Wiese M
ChemMedChem; 2016 Nov; 11(21):2422-2435. PubMed ID: 27735138
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.
Kraege S; Stefan K; Köhler SC; Wiese M
ChemMedChem; 2016 Nov; 11(22):2547-2558. PubMed ID: 27785905
[TBL] [Abstract][Full Text] [Related]
3. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M
Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033
[TBL] [Abstract][Full Text] [Related]
4. Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.
Peña-Solórzano D; Scholler M; Bernhardt G; Buschauer A; König B; Ochoa-Puentes C
ACS Med Chem Lett; 2018 Aug; 9(8):854-859. PubMed ID: 30128080
[TBL] [Abstract][Full Text] [Related]
5. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
7. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Pirker C; Koblmüller B; Pfeiler G; Hacker S; Berger W; Heffeter P; Cichna-Markl M
Oncotarget; 2016 Nov; 7(45):73347-73369. PubMed ID: 27689338
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Wiese M
J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
[TBL] [Abstract][Full Text] [Related]
11. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
12. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin.
Dornetshuber R; Heffeter P; Sulyok M; Schumacher R; Chiba P; Kopp S; Koellensperger G; Micksche M; Lemmens-Gruber R; Berger W
Mol Nutr Food Res; 2009 Jul; 53(7):904-20. PubMed ID: 19517454
[TBL] [Abstract][Full Text] [Related]
13. ABCG2/BCRP: Specific and Nonspecific Modulators.
Peña-Solórzano D; Stark SA; König B; Sierra CA; Ochoa-Puentes C
Med Res Rev; 2017 Sep; 37(5):987-1050. PubMed ID: 28005280
[TBL] [Abstract][Full Text] [Related]
14. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
16. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
[TBL] [Abstract][Full Text] [Related]
17. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
18. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
19. Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
Obreque-Balboa JE; Sun Q; Bernhardt G; König B; Buschauer A
Eur J Med Chem; 2016 Feb; 109():124-33. PubMed ID: 26774038
[TBL] [Abstract][Full Text] [Related]
20. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]